A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu - Concepedia

Concepedia

Publication | Open Access

A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu

DOI Full Paper Access

84

Citations

23

References

2009

Year

Prema P. Peethambaram, Michelle Melisko, Kristine Rinn, Steven R. Alberts, Nicole Provost, Lori Jones, Robert B. Sims, Lisa R. C. Lin, Mark W. Frohlich, John W. Park

Clinical Cancer Research

Abstract

Autologous active cellular immunotherapy with lapuleucel-T stimulated an immune response specific to the immunizing antigen and seemed to be well tolerated. Further clinical studies to assess the clinical benefit for patients with HER/2-neu-expressing breast, ovarian, and colorectal cancer are warranted.

References

	Year	Citations

Page 1